
Dollars in millions
Balance at December 31, 2025	$	21,754
Currency translation and other adjustments	(14)
Balance at June 30, 2026	$	21,740


	Estimated Useful Lives	June 30, 2026						December 31, 2025
Dollars in millions		Gross carrying amounts		Accumulated amortization		Other intangible assets, net		Gross carrying amounts		Accumulated amortization		Other intangible assets, net
R&D technology	6 years	$	1,980	$	(770)	$	1,210	$	1,980	$	(605)	$	1,375
Acquired marketed product rights	3 – 17 years	61,353		(52,323)		9,030		61,385		(51,646)		9,739
Capitalized software	3 – 10 years	1,509		(1,133)		376		1,453		(1,064)		389
IPRD		6,770		—		6,770		7,600		—		7,600
Total		$	71,612	$	(54,226)	$	17,387	$	72,418	$	(53,315)	$	19,103

Amortization expense of Other intangible assets was $471 million and $943 million during the three and six months ended June 30, 2026 and $864 million and $1.7 billion for the three and six months ended June 30, 2025, respectively.

During the three and six months ended June 30, 2026, IPRD impairment charges of $420 million and $830 million, respectively, were recorded in Research and development expense. The charges primarily reflect a partial write-down of an oncology asset based on recent clinical results and development plan changes. The six months ended June 30, 2026 also includes a partial write-down of a radiopharmaceutical asset driven by an indication realignment within our portfolio.

During the three months ended June 30, 2025, $300 million of IPRD impairment charges were recorded in Research and development expense for two oncology assets. The charges represented a partial write-down of each asset driven by revised cash flow projections and updated clinical development timelines.